Natick firm partners with UK cancer charity to study new therapy
Courtesy | Aleta Biotherapeutics
Natick-based Aleta Biotherapeutics has announced a partnership with Cancer Research UK to study Aleta’s cancer therapy candidate.
Aleta is a privately held immunoncology company focused on cellular therapeutics, while Cancer Research UK is the world’s leading cancer charity dedicated to saving lives, according to a release from Aleta.
As part of the partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr. Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester, U.K.
ALETA-001 has been developed to benefit people with B-cell lymphoma and leukemia whose disease has progressed after receiving CD19 CAR-T cell therapy, according to Aleta. The company hopes ALETA-001 will offer a new therapy for these patients who have limited treatment options.
Aleta will retain the rights to further develop and commercialize ALETA-001 and will receive a licence to the results of the clinical trial from Cancer Research UK in return for undisclosed success-based milestone and royalty payments.
WBJ Web Partners
Most Recent
Most Recent
0 Comments